Top Page
Acrux
(OTC:ACR)
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
Acrux Business Overview & Revenue Model
Acrux Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19M | 1.19M | 5.09M | 8.43M | 1.72M | 1.34M |
| Gross Profit | -1.12M | 1.19M | 1.13M | 1.95M | -4.65M | -7.59M |
| EBITDA | -8.76M | -5.17M | -8.06M | -2.79M | -12.29M | -15.59M |
| Net Income | -5.95M | -5.95M | -5.80M | -764.00K | -9.83M | -12.63M |
Balance Sheet | ||||||
| Total Assets | 7.22M | 7.22M | 8.96M | 14.30M | 15.27M | 24.20M |
| Cash, Cash Equivalents and Short-Term Investments | 863.00K | 863.00K | 2.94M | 6.23M | 5.83M | 15.27M |
| Total Debt | 3.63M | 3.63M | 3.70M | 2.35M | 2.08M | 2.23M |
| Total Liabilities | 6.20M | 6.20M | 5.69M | 5.60M | 6.18M | 5.73M |
| Stockholders Equity | 1.02M | 1.02M | 3.28M | 8.70M | 9.09M | 18.47M |
Cash Flow | ||||||
| Free Cash Flow | -5.48M | -5.48M | -4.58M | 584.00K | -9.28M | -11.52M |
| Operating Cash Flow | -5.47M | -5.47M | -4.30M | 703.00K | -8.82M | -11.41M |
| Investing Cash Flow | -5.00K | -5.00K | -276.00K | -119.00K | -465.00K | -102.00K |
| Financing Cash Flow | 3.39M | 3.39M | 1.29M | -183.00K | -155.00K | 17.58M |
Acrux Technical Analysis
Acrux Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$9.39M | -19.84 | -8.72% | ― | ― | 71.10% | |
54 Neutral | AU$34.92M | -8.33 | -16.65% | ― | ― | -672.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$6.16M | -0.85 | -270.27% | ― | -76.63% | 12.00% | |
42 Neutral | AU$10.93M | -1.69 | -469.35% | ― | ― | 46.28% | |
39 Underperform | AU$13.07M | -3.57 | -90.15% | ― | -93.83% | 20.00% |
Acrux Corporate Events
Acrux Ltd has announced a change in the director’s interest, with Director John Warmbrunn acquiring 8,000,000 unlisted options. This change was approved at the company’s AGM on 25 November 2025, and it highlights a significant increase in the director’s stake, potentially impacting the company’s governance and signaling confidence in its future prospects.
Acrux Limited has announced the cessation of 112,000 performance rights due to the lapse of conditional rights, as the conditions were not met or have become incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perception regarding the company’s ability to meet performance targets.
Acrux Limited has announced a change in the interests of its director, Geoffrey Brooke, involving the acquisition of 2,866,719 rights as approved at the company’s Annual General Meeting in November 2025. This change reflects an increase in the director’s direct holdings, which may impact the company’s governance and shareholder interests.
Acrux Ltd announced a change in the director’s interest, with Tim Oldham acquiring 2,866,719 unlisted rights, as approved at the company’s AGM on November 25, 2025. This change reflects a strategic move to align the director’s interests with the company’s long-term goals, potentially impacting stakeholder confidence and Acrux’s market positioning.
Acrux Ltd has announced a change in the director’s interest, specifically involving Don Brumley. The company has issued 2,866,719 unlisted rights to Brumley, which were approved at the recent AGM held on November 25, 2025. This change reflects an increase in Brumley’s holdings, indicating a potential strategic alignment or confidence in the company’s future prospects.
Acrux Limited has announced a change in the interests of its director, Ross Dobinson, with the acquisition of 4,514,260 unlisted rights issued in December 2025. This change follows approval at the company’s Annual General Meeting in November 2025, indicating a strategic move to align director incentives with company performance, potentially impacting Acrux’s governance and stakeholder confidence.
Acrux Limited announced the results of its Annual General Meeting held on November 25, 2025, where all resolutions were passed, including a special resolution for a 10% placement capacity. This outcome reflects strong shareholder support and positions Acrux to potentially expand its market presence and operational capabilities.
Acrux Ltd’s recent announcement at their Annual General Meeting highlights the company’s strategic focus on navigating market challenges and leveraging its expertise in topical pharmaceuticals. The release underscores the inherent risks and uncertainties in the pharmaceutical industry, emphasizing the company’s commitment to addressing these challenges while cautioning stakeholders about the unpredictability of future performance.
Acrux Ltd, a company listed on the ASX, has announced a change in the director’s interest, specifically regarding Don Brumley. On November 24, 2025, Brumley exercised his vested unlisted rights issued in 2024, resulting in the acquisition of 448,334 ordinary shares. This change increases his holdings to 7,375,700 ordinary shares and 2,285,714 options. The transaction did not occur during a closed period, indicating compliance with trading regulations.
Acrux Limited has announced the quotation of 1,345,002 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 24, 2025. This move is part of the company’s strategy to enhance its market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility and tradability of its shares.
Acrux Limited has received a $0.4 million advance from Radium Capital as part of its FY26 R&D Tax Incentive, representing 80% of the estimated rebate for the quarter ending September 2025. This funding, which incurs a 17% annual interest, will support the development of Acrux’s products and manage working capital, highlighting the company’s ongoing commitment to innovation and financial strategy.
Acrux Limited reported a significant increase in its profit share income for the September quarter, surpassing the total income of the previous financial year. The company’s revenue growth is driven by products launched in FY25, with notable contributions from Nitroglycerin ointment and Dapsone gels. Additionally, Acrux received a substantial R&D Tax Incentive Rebate from the Australian Tax Office and repaid short-term advances from Radium Capital. The company’s strategic focus on its portfolio of topical generics is expected to continue supporting revenue growth in FY26.
Acrux Limited reported a significant increase in its September quarterly profit share income, surpassing the total income of the previous financial year. This growth is attributed to the successful market penetration of its recently launched products, including Nitroglycerin Ointment and Dapsone Gel, which have achieved substantial market shares. The company also received a $3.04 million R&D Tax Incentive Rebate from the Australian Tax Office, which facilitated the repayment of short-term advances from Radium Capital. Acrux’s strategic focus on expanding its portfolio of generic products and exploring international markets is expected to drive further revenue growth and enhance its industry positioning.
Acrux Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, where shareholders will discuss key resolutions including the re-election of Dr. Geoff Brooke as a director, the issuance of rights to non-executive directors, and options to the CEO under the company’s Omnibus Equity Plan. Additionally, shareholders will consider approving a 10% placement capacity for equity securities, which could impact the company’s capital structure and shareholder value.
Acrux Limited has announced the date for its upcoming Annual General Meeting (AGM), scheduled for November 25, 2025, in Melbourne. A key agenda item will be the election of directors, with nominations accepted until October 10, 2025. This meeting is significant for stakeholders as it will shape the company’s leadership and potentially influence its strategic direction.